Thorac Cardiovasc Surg
DOI: 10.1055/s-0041-1723000
Original Cardiovascular

Ovine Biosynthetic Grafts for Aortoiliac Reconstructions in Nonsterile Operative Fields

Hazem El Beyrouti
1  Department of Cardiothoracic and Vascular Surgery, Johannes Gutenberg University Hospital Mainz, Mainz, Rheinland-Pfalz, Germany
,
Mohammad Bashar Izzat
2  Department of Surgery, Damascus University, Damascus, Syrian Arab Republic
,
Angela Kornberger
1  Department of Cardiothoracic and Vascular Surgery, Johannes Gutenberg University Hospital Mainz, Mainz, Rheinland-Pfalz, Germany
,
Nancy Halloum
1  Department of Cardiothoracic and Vascular Surgery, Johannes Gutenberg University Hospital Mainz, Mainz, Rheinland-Pfalz, Germany
,
Kathrin Dohle
1  Department of Cardiothoracic and Vascular Surgery, Johannes Gutenberg University Hospital Mainz, Mainz, Rheinland-Pfalz, Germany
,
Tran Tong Trinh
3  Department of Vascular Surgery, Faculty of Medicine, University of Cologne, Koln, Nordrhein-Westfalen, Germany
,
Christian-Friedrich Vahl
1  Department of Cardiothoracic and Vascular Surgery, Johannes Gutenberg University Hospital Mainz, Mainz, Rheinland-Pfalz, Germany
,
Bernhard Dorweiler
3  Department of Vascular Surgery, Faculty of Medicine, University of Cologne, Koln, Nordrhein-Westfalen, Germany
› Author Affiliations

Abstract

Background Prosthetic vascular grafts placed surgically or via endovascular techniques can be subject to the risk of life-threatening graft infections. The Omniflow II vascular prosthesis is a biosynthetic graft that was reported to have favorable properties in resisting infections.

Materials and Methods We retrospectively reviewed our 3 years' experience of using the Omniflow II prostheses for aortoiliac reconstructions in patients considered to carry a substantial risk of subsequent prosthetic graft infections (prevention group) as well as in patients with actively infected prosthetic vascular grafts (treatment group).

Results Aorto-bi-iliac (n = 4) and aortobifemoral (n = 12) vascular reconstructions were performed using bifurcated Omniflow II prostheses in nine patients in the prevention group and seven patients in the treatment group. During mean follow-up of 28.6 ± 17.2 months, there was one case of graft infection (6.3%) and graft thrombosis (6.3%) with subsequent successful thrombectomy. Early and late surgical revisions were required in eight (50%) and two (12.6%) patients, respectively. All graft prostheses were patent at last follow-up.

Conclusion Using bifurcated Omniflow II vascular prostheses in patients with or at a high risk of vascular graft infection is advisable, and is associated with acceptable reinfection and patency rates.



Publication History

Received: 14 October 2020

Accepted: 14 December 2020

Publication Date:
04 February 2021 (online)

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany